CJC-1295

CJC-1295 (modified GHRH analog)

Long-acting GHRH analog · pairs with ipamorelin for sustained GH release

FDA Status

Not FDA-approved · Investigational

Class

GHRH analog · with or without DAC (drug affinity complex)

Sequence

Modified GHRH 1-29 sequence

Half-life

CJC-1295 (no DAC): ~30 min · With DAC: ~6-8 days

Mechanism of action

• GHRH receptor agonism → pituitary GH release
• DAC variant binds albumin → extended half-life
• Increases GH and IGF-1 baseline (vs pulsatile)
• Synergistic with ghrelin agonists (ipamorelin, GHRP-6)

Research areas

• Growth hormone insufficiency
• Anti-aging and body composition research
• Sleep architecture (GH/sleep relationship)
• Wound healing co-administration

Evidence and clinical data

Phase II trials demonstrated 7-10 day sustained GH/IGF-1 elevation with DAC variant. Limited Phase III. Theoretical concern: continuous GHRH signal vs natural pulsatile pattern.

Safety profile

Generally tolerated. Concern around chronically elevated IGF-1 and theoretical cancer risk (no human evidence). DAC variant flagged for sustained signal vs physiological pulsatility.